Johnson Matthey (JMAT) Earns Sell Rating from UBS Group

Share on StockTwits

Johnson Matthey (LON:JMAT)‘s stock had its “sell” rating restated by research analysts at UBS Group in a research note issued to investors on Thursday, investing.thisismoney.co.uk reports.

Several other equities analysts also recently issued reports on the stock. Deutsche Bank reissued a “buy” rating and set a GBX 4,500 ($58.80) price target on shares of Johnson Matthey in a report on Monday, October 8th. Berenberg Bank reissued a “buy” rating and set a GBX 4,300 ($56.19) price target on shares of Johnson Matthey in a report on Monday, September 17th. Credit Suisse Group reissued an “outperform” rating on shares of Johnson Matthey in a report on Thursday, August 23rd. Finally, Liberum Capital reissued a “buy” rating on shares of Johnson Matthey in a report on Wednesday, September 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of GBX 3,962.50 ($51.78).

Shares of JMAT stock opened at GBX 2,914 ($38.08) on Thursday. Johnson Matthey has a 12-month low of GBX 2,681 ($35.03) and a 12-month high of GBX 3,511 ($45.88).

In other Johnson Matthey news, insider Annette Kelleher sold 985 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of GBX 3,709 ($48.46), for a total value of £36,533.65 ($47,737.68). Also, insider John Walker bought 12 shares of the company’s stock in a transaction on Wednesday, October 17th. The stock was bought at an average cost of GBX 3,093 ($40.42) per share, with a total value of £371.16 ($484.99). Over the last ninety days, insiders acquired 36 shares of company stock valued at $123,396.

Johnson Matthey Company Profile

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.

Featured Story: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Johnson Matthey (LON:JMAT)

Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bell Rock Capital LLC Takes Position in iShares U.S. Aerospace & Defense ETF
Bell Rock Capital LLC Takes Position in iShares U.S. Aerospace & Defense ETF
Bell Rock Capital LLC Purchases New Stake in Church & Dwight Co., Inc.
Bell Rock Capital LLC Purchases New Stake in Church & Dwight Co., Inc.
CSX Co.  Shares Bought by Capital World Investors
CSX Co. Shares Bought by Capital World Investors
Union Pacific Co.  Shares Bought by Capital World Investors
Union Pacific Co. Shares Bought by Capital World Investors
Cantor Fitzgerald Lowers GW Pharmaceuticals PLC-  Price Target to $193.00
Cantor Fitzgerald Lowers GW Pharmaceuticals PLC- Price Target to $193.00
Roku  Upgraded to “Buy” at DA Davidson
Roku Upgraded to “Buy” at DA Davidson


© 2006-2018 Ticker Report